417721-78-9

Basic information

• Product Name: 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine
• Synonyms: 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine
• CAS NO: 417721-78-9
• Molecular Weight: 255.233
• Mol File: 417721-78-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine(417721-78-9)
• EPA Substance Registry System: 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine(417721-78-9)

Safety Data

• Hazardous Substances Data: 417721-78-9(Hazardous Substances Data)

Upstream product

• 100-02-7 4-nitro-phenol 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 417721-79-0 4-((1H-pyrrolo [2,3-b]pyridin-4-yl)oxy)aniline 

Relevant articles and documents

Compound and application thereof in preparation of drugs for treating diseases caused by high expression of Flt3/c-Met kinase

The invention belongs to the technical field of chemical drug synthesis, and provides a compound and application thereof in preparation of drugs for treating diseases caused by high expression of Flt3/cMet kinase. The compound provided by the invention is prepared by amidation reaction of an intermediate A and an intermediate B. The compound provided by the invention has a strong effect of inhibiting Flt3/cMet kinase. The invention also discloses application of the compound and salt, solvate or prodrug thereof, or application of a pharmaceutical composition composed of one of the compound, salt, hydrate, solvate and prodrug thereof and an excipient in preparation of drugs for treating diseases caused by abnormal high expression of Flt3/cMet kinase, and application in drugs for treating and/or preventing proliferative diseases or cancers.

Preparation and application of pyridoheterocycle compound with 1-aryl-4-oxy-1,4-dihydroquinoline structure

The invention relates to preparation and application of a pyridoheterocycle compound with a 1-aryl-4-oxy-1,4-dihydroquinoline structure as shown in general formula I, as well as pharmaceutically acceptable salt, hydrate, solvate and prodrugs thereof. The substituted groups are R, R1, X, Y and Z. The invention further relates to a compound as shown in the general formula I having a strong effect ofinhibiting c-Met kinase, and application of the compounds, pharmaceutically acceptable salt, hydrate, solvate and prodrugs thereof in preparation of medicines for treating diseases caused by abnormally activated high expression of c-Met kinase, particularly application in preparation of medicines for treating and/or preventing cancers.

Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors

Two series of aromatic hydrazone derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety (7a–r, 8a–i, 12a–b, 13a–c, 16a–d and 17a–e) were designed, synthesized and evaluated for the IC50 values against four cancer cell lines (A549, HepG2, MCF-7and PC-3). Two selected compounds (7c and 17e) were further evaluated for the activity against c-Met, Flt-3, VEGFR-2 and EGFR kinases. The data indicated that targets compounds were selective for c-Met kinase. And the most promising compound 7c was further studied in terms of dose-dependent, time-dependent and cell apoptosis. Most of the compounds showed excellent cytotoxicity activity, especially the most promising compound 7c with the IC50 values of 0.82 ± 0.08 μM, 1.00 ± 0.11 μM, 0.93 ± 0.28 μM and 0.92 ± 0.17 μM against A549, HepG2, MCF-7 and PC-3 cell lines and 0.506 μM against c-Met kinase. Structure–activity relationships (SARs) and docking studies indicated that the activities of the phenyl hydrazone derivatives (7a–r and 8a–i) were superior to that of the heterocyclic hydrazone series (12a–b, 13a–c, 16a–d and 17a–e). What's more, the further studies indicated that the target compounds can induce apoptosis of A549 cells and arrest efficiently the cell cycle progression in G2/M phase of A549 cells.